EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Effectiveness of the Approved Nirmatrelvir/Ritonavir and Molnupiravir Regimens for Treatment of Mild/Moderate Laboratory-Confirmed SARS-CoV-2 Infection in Patients Aged 18–64 Years in Hong Kong: A Population-Based Cohort Study

George N Okoli, Yun Lin, Peng Wu, Benjamin J Cowling

Clinical Drug Investigation · 2026-09 · 46 (9) · 1047-1065

DOI: 10.1007/s40261-026-01575-7 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Drug Investigation, online erschienen am 03.07.2026. Verfasst von George N Okoli und 3 weiteren Autor:innen. Beteiligte Einrichtung: World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medic…. Hauptthemen laut MEDLINE: Ritonavir, COVID-19 Drug Treatment, Antiviral Agents, COVID-19. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirCOVID-19 Drug TreatmentAntiviral AgentsCOVID-19HumansAdultMaleHong KongMiddle AgedFemaleAdolescentYoung AdultCohort StudiesSARS-CoV-2Drug CombinationsTreatment OutcomeLopinavir

Substanzen

RitonavirAntiviral AgentsDrug Combinationslopinavir-ritonavir drug combinationLopinavir

Autor:innen und Institutionen

  • World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administ…
  • Department of Family Medicine, University of Michigan, Ann Arbor, Michigan, USA. okolign@hku.hk.
  • Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administrative Region of China, Hong Kong. bcowling@hku.hk.

Förderung

  • Health Bureau

Zitieren

APA

Okoli, G. N., Lin, Y., Wu, P., & Cowling, B. J. (2026). Effectiveness of the Approved Nirmatrelvir/Ritonavir and Molnupiravir Regimens for Treatment of Mild/Moderate Laboratory-Confirmed SARS-CoV-2 Infection in Patients Aged 18–64 Years in Hong Kong: A Population-Based Cohort Study. Clinical Drug Investigation, 46(9), 1047-1065. https://doi.org/10.1007/s40261-026-01575-7

Vancouver

Okoli GN, Lin Y, Wu P, Cowling BJ. Effectiveness of the Approved Nirmatrelvir/Ritonavir and Molnupiravir Regimens for Treatment of Mild/Moderate Laboratory-Confirmed SARS-CoV-2 Infection in Patients Aged 18–64 Years in Hong Kong: A Population-Based Cohort Study. Clinical Drug Investigation. 2026;46(9):1047-1065. doi:10.1007/s40261-026-01575-7

BibTeX
@article{Okoli2026,
  author = {Okoli, George N and Lin, Yun and Wu, Peng and Cowling, Benjamin J},
  title = {Effectiveness of the Approved Nirmatrelvir/Ritonavir and Molnupiravir Regimens for Treatment of Mild/Moderate Laboratory-Confirmed SARS-CoV-2 Infection in Patients Aged 18–64 Years in Hong Kong: A Population-Based Cohort Study},
  journal = {Clinical Drug Investigation},
  year = {2026},
  volume = {46},
  number = {9},
  pages = {1047--1065},
  doi = {10.1007/s40261-026-01575-7}
}
Kostenlos starten →